ORAL BIOLOGICS MARKET ANALYSIS

Oral Biologics Market, By Drug Class (Glucagon-like Peptide 1 (GLP-1) Receptor Agonist, Hormone, Recombinant Enzyme, Guanylate Cyclase-C Agonist, Somatostatin Analogue, Others), By Disease Indication (Diabetes, Hyperoxaluria, Acromegaly, Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC), Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Aug 2023
Code : CMI989
Pages :197
Formats :
Excel and PDF
Industry : Biotechnology

Market News

Global Oral Biologics Market: Key Developments

In January 2020, the European Medicines Agency recommended granting a marketing authorization in the European Union (EU) for oral Rybelsus (semaglutide) for the treatment of adults with insufficiently controlled type 2 diabetes to improve glycaemic control as an adjunct to diet and exercise. Rybelsus is the first glucagon-like peptide (GLP-1) receptor agonist treatment, a class of non-insulin medicines for people with type 2 diabetes.

In June 2020, the U.S. FDA approved MYCAPSSA, the first and only oral somatostatin analogue (SSA), for the long-term maintenance treatment of acromegaly patients who had responded to and tolerated treatment with octreotide or lanreotide. The Mycapssa is manufactured by Chiasma, Inc., a commercial-stage biopharmaceutical company.

In February 2022, Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company, announced the development of RaniPill HC, a high-capacity oral biologics device. The newly launched RaniPill HC is capable of delivering up to a 500%-plus higher drug payload than Rani’s existing oral biologic capsule.